ESTABLISHMENT OF AIDS TREATMENT EVALUATION UNITS

建立艾滋病治疗评估单位

• 批准号: 3595961
• 负责人: HENRY H BALFOUR
• 金额: --
• 依托单位: UNIVERSITY OF MINNESOTA
• 依托单位国家: 美国
• 财政年份: 1987
• 资助国家: 美国
• 起止时间: 1987-01-02 至 1991-06-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3595961
• 关键词: AIDS; AIDS therapy; cell sorting; combination chemotherapy; dosage; drug administration rate /duration; drug adverse effect; drug metabolism; drug screening /evaluation; human immunodeficiency virus 1; human subject; human therapy evaluation; humoral immunity; immunologic skin test; immunopathology chemotherapy; neoplasm /cancer classification /staging; nuclear medicine; opportunistic infections; pharmacokinetics; virus classification

This contract is one of a number of awards solicited under a single RFP designed to put in place a number of clinical research facilities that would have the capability of performing Phase 1 and Phase 2 clinical studies in patients infected with HIV (Human Immunodeficiency Virus). These studies are necessary for the NIAID to identify a safe and possibly efficacious treatment regimen for this infection. The studies will provide information, in addition, on the pharmacokinetics of the drugs evaluated and their metabolites. The contractor will be responsible for assessing the patient's response therapy using performance status, drug response, pharmacokinetic assays, and toxicity criteria designated in advance. The contractor will be responsible for performing viral isolation assays from a variety of clinical samples, for evaluating immunologic status prior to, during, and after therapy, and for performing in-depth pharmacokinetic analysis on a subset of patients treated. Clinical status of the patients will be regularly monitored. Data will be submitted by remote entry to a centralized coordinating center. Investigators will meet regularly with the AIDS Drug Selection Committee to discuss current and future studies and resolve technical issues through focused workshops.

该合同是根据单一招标招标的众多合同之一

项目成果

Purified human T cells stimulated with cross-linked anti-CD3 monoclonal antibody OKT3: rIL-1 is a co-stimulatory factor for CD4+CD29+CD45RA- T cells.

用交联抗 CD3 单克隆抗体 OKT3 刺激的纯化人 T 细胞：rIL-1 是 CD4 CD29 CD45RA-T 细胞的共刺激因子。

• DOI: 10.1111/j.1365-3083.1990.tb02930.x
• 发表时间: 1990
• 期刊: Scandinavian journal of immunology
• 影响因子: 3.7
• 作者: Panzer,S;Geller,RL;Bach,FH
• 通讯作者: Bach,FH

Concurrent zidovudine levels in semen and serum determined by radioimmunoassay in patients with AIDS or AIDS-related complex.

通过放射免疫测定同时测定艾滋病或艾滋病相关综合症患者精液和血清中的齐多夫定水平。

• 发表时间: 1988
• 期刊: JAMA
• 作者: Henry,K;Chinnock,BJ;Quinn,RP;Fletcher,CV;deMiranda,P;BalfourJr,HH
• 通讯作者: BalfourJr,HH

Varicella zoster virus infections in immunocompromised hosts. A review of the natural history and management.

• 发表时间: 1988
• 期刊: The American journal of medicine
• 作者: H. Balfour

Practical diagnostic testing for human immunodeficiency virus.

人类免疫缺陷病毒的实用诊断测试。

• DOI: 10.1128/cmr.1.1.124
• 发表时间: 1988
• 期刊: Clinical microbiology reviews
• 影响因子: 36.8
• 作者: Jackson,JB;BalfourJr,HH
• 通讯作者: BalfourJr,HH

Prevalence of cytomegalovirus antibody in hemophiliacs and homosexuals infected with human immunodeficiency virus type 1.

感染人类免疫缺陷病毒 1 型的血友病患者和同性恋者中巨细胞病毒抗体的患病率。

• DOI: 10.1046/j.1537-2995.1988.28288179029.x
• 发表时间: 1988
• 期刊: Transfusion
• 影响因子: 2.9
• 作者: Jackson,JB;Erice,A;Englund,JA;Edson,JR;BalfourJr,HH
• 通讯作者: BalfourJr,HH